Diagnostic accuracy of intrathecal kappa free light chains compared with OCBs in MS.
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
16
12
2019
accepted:
20
04
2020
entrez:
13
6
2020
pubmed:
13
6
2020
medline:
14
9
2021
Statut:
epublish
Résumé
To determine what kappa free light chain (KFLC) metric has the highest capacity to separate healthy patients from patients with MS, we evaluated the sensitivity, specificity, and the overall diagnostic accuracy of 4 different KFLC metrics. To assess the usefulness of KFLC in the diagnostics of MS, we compared the different KFLC metrics with oligoclonal bands (OCBs), the current gold standard biochemical method to demonstrate intrathecal antibody production. CSF and plasma were collected from patients with confirmed or suspected MS, other neurological diseases, as well as symptomatic and healthy controls between May 2017 and May 2018 (n = 335) at the Department of Neurology, Karolinska University Hospital, as part of routine diagnostic workup. KFLC analysis and isoelectric focusing for the detection of oligoclonal bands (OCB) were determined and correlated with diagnosis. Receiver operating characteristic (ROC) curve analysis was used to determine accuracy. OCBs yielded a sensitivity of 87% and a specificity of 100%. All KFLC metrics showed a high sensitivity (89%-95%) and specificity (95%-100%). Using the optimal cutoff according to the Youden Index resulted for the KFLC intrathecal fraction in a cutoff of -0.41 with a sensitivity of 95% and a specificity of 97% and for CSF KFLC/CSF albumin with a cutoff of 1.93 × 10 All evaluated KFLC metrics have excellent accuracy, and both KFLC intrathecal fraction and CSF KFLC/CSF albumin are at least as good as OCB in separating patients with MS from a control group. This study provides Class III evidence that CSF KFLC accurately distinguishes patients with MS from healthy controls.
Identifiants
pubmed: 32527760
pii: 7/4/e775
doi: 10.1212/NXI.0000000000000775
pmc: PMC7309528
pii:
doi:
Substances chimiques
Immunoglobulin kappa-Chains
0
Oligoclonal Bands
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Mult Scler. 2017 Oct;23(11):1496-1505
pubmed: 27899552
Neurology. 2009 Dec 1;73(22):1914-22
pubmed: 19949037
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Clin Lab. 2017 Mar 1;63(3):551-559
pubmed: 28271695
PLoS One. 2014 Feb 25;9(2):e89945
pubmed: 24651567
Ann Neurol. 2003 Feb;53(2):222-6
pubmed: 12557289
J Neuroimmunol. 2014 Nov 15;276(1-2):175-9
pubmed: 25146968
Mult Scler. 2019 Nov;25(13):1809-1818
pubmed: 30381987
Clin Chim Acta. 2019 Oct;497:153-162
pubmed: 31351929
Clin Chem Lab Med. 2018 Mar 28;56(4):609-613
pubmed: 29087953
Mult Scler. 2016 Apr;22(4):502-10
pubmed: 26199348
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Mult Scler Int. 2016;2016:2303857
pubmed: 28116160
Clin Chem Lab Med. 2018 Jun 27;56(7):1071-1080
pubmed: 29455184
Ann Indian Acad Neurol. 2009 Oct;12(4):226-30
pubmed: 20182569
Clin Chem. 1984 Jul;30(7):1246-9
pubmed: 6375900
J Neuroimmunol. 2017 Aug 15;309:31-33
pubmed: 28601282
J Cell Mol Med. 2018 Oct;22(10):5151-5154
pubmed: 30054982
J Neurol. 2008 Oct;255(10):1508-14
pubmed: 18685917
J Neurol. 1974;207(1):45-52
pubmed: 4142885
J Neuroimmunol. 2013 Oct 15;263(1-2):116-20
pubmed: 23916392
J Clin Invest. 2005 Jan;115(1):187-94
pubmed: 15630459
PLoS One. 2015 Nov 25;10(11):e0143375
pubmed: 26606531
Mult Scler. 2013 Nov;19(13):1802-9
pubmed: 23695446